Aldeyra Therapeutics appoints Chip Clark to board of directors

Aldeyra Therapeutics, Inc.

William (Chip) Clark elected as Class I director on April 17, 2025; term expires at 2027 annual meeting.
Board size increased to eight upon Clark's election.
Clark received option to purchase 76,760 shares at closing price on April 17, 2025, vesting over 3 years.
Annual director fee of $40,000 plus eligibility for annual option grant worth ~$130,000.
Clark is co-founder/CEO of Vibrant Biomedicines, former CEO of Genocea Biosciences.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William (Chip) Clark

Director

ALDX · Aldeyra Therapeutics, Inc.

Effective: 2025-04-17
Filed: April 17, 2025, 7:59 PM ET

the Board elected William (Chip) Clark as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William (Chip) Clark was elected as Director at Aldeyra Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

the Board elected William (Chip) Clark as a Class I director

View on SEC.gov

Aldeyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-032947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.